 Zynerba Pharmaceuticals Inc NASDAQ: ZYNE announced positive top-line results from the Phase 2 INSPIRE trial of Zygel Transdermal CBD gel on pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome. The total score and all five subscales of the Anxiety, Depression. 